{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:01:44Z","timestamp":1785430904109,"version":"3.56.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11912-025-01639-5","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T08:00:41Z","timestamp":1739347241000},"page":"258-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma"],"prefix":"10.1007","volume":"27","author":[{"given":"Bhavesh","family":"Mohan Lal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"5","key":"1639_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335\u201348.","journal-title":"Nat Rev Cancer"},{"issue":"Supplement 1","key":"1639_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2022-158219","volume":"140","author":"J Cote","year":"2022","unstructured":"Cote J, Leblanc R, Chu MP, McCurdy A, Masih-Khan E, Kardjadj M, et al. Real-world results of autologous stem cell transplantation in newly diagnosed patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database. Blood. 2022;140(Supplement 1):289\u201391.","journal-title":"Blood"},{"issue":"20","key":"1639_CR3","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043\u201351.","journal-title":"Blood"},{"issue":"16suppl","key":"1639_CR4","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1200\/JCO.2023.41.16_suppl.8059","volume":"41","author":"S Al Hadidi","year":"2023","unstructured":"Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Zangari M, et al. Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. J Clin Oncol. 2023;41(16suppl):8059\u20138059.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1639_CR5","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood"},{"issue":"1","key":"1639_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"K Ra","year":"2023","unstructured":"Ra K, Ma G, Te W, Ja L, Mq L. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2023;78(1):21\u201333. https:\/\/doi.org\/10.4065\/78.1.21.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"1639_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0609.2005.00532.x","volume":"75","author":"A Anagnostopoulos","year":"2005","unstructured":"Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol. 2005;75(5):370\u20135.","journal-title":"Eur J Haematol"},{"issue":"13","key":"1639_CR8","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068\u201374.","journal-title":"Blood"},{"issue":"11","key":"1639_CR9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761\u20137.","journal-title":"Haematologica"},{"issue":"6","key":"1639_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.13383","volume":"169","author":"M Weinstock","year":"2015","unstructured":"Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851\u20138.","journal-title":"Br J Haematol"},{"issue":"10","key":"1639_CR11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98(10):1540\u20139.","journal-title":"Am J Hematol"},{"issue":"1","key":"1639_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","volume":"96","author":"S Mangiacavalli","year":"2017","unstructured":"Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96(1):73\u201380.","journal-title":"Ann Hematol"},{"issue":"1","key":"1639_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195\u2013200.","journal-title":"Ann Oncol"},{"issue":"5","key":"1639_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/leu.2015.15","volume":"29","author":"R Khan","year":"2015","unstructured":"Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia. 2015;29(5):1195\u2013201.","journal-title":"Leukemia"},{"issue":"3","key":"1639_CR15","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1038\/bcj.2015.20","volume":"5","author":"WI Gonsalves","year":"2015","unstructured":"Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5(3):e296.","journal-title":"Blood Cancer J"},{"issue":"15","key":"1639_CR16","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1639_CR17","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2214\/AJR.13.10724","volume":"203","author":"M D\u2019Anastasi","year":"2014","unstructured":"D\u2019Anastasi M, Notohamiprodjo M, Schmidt GP, D\u00fcrr HR, Reiser MF, Baur-Melnyk A. Tumor load in patients with multiple myeloma: \u03b22-Microglobulin levels Versus whole-body MRI. Am J Roentgenol. 2014;203(4):854\u201362.","journal-title":"Am J Roentgenol"},{"issue":"1","key":"1639_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.ajkd.2015.07.025","volume":"67","author":"LA Inker","year":"2016","unstructured":"Inker LA, Tighiouart H, Coresh J, Foster MC, Anderson AH, Beck GJ, et al. GFR Estimation using \u03b2-Trace protein and \u03b22-Microglobulin in CKD. Am J Kidney Dis off J Natl Kidney Found. 2016;67(1):40\u20138.","journal-title":"Am J Kidney Dis off J Natl Kidney Found"},{"issue":"15suppl","key":"1639_CR19","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1200\/JCO.2020.38.15_suppl.8544","volume":"38","author":"G Lin","year":"2020","unstructured":"Lin G, Hari P, Chhabra S, Hamadani M, D\u2019Souza A, Szabo A, et al. The significance of beta-II microglobulin (\u03b22M) and International Staging System (ISS) in multiple myeloma (MM) patients (pts.) With renal impairment (RI). J Clin Oncol. 2020;38(15suppl):8544\u20138544.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1639_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.7326\/0003-4819-115-12-931","volume":"115","author":"MA Dimopoulos","year":"1991","unstructured":"Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for Drug Resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931\u20135.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1639_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","volume":"85","author":"E Terpos","year":"2010","unstructured":"Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol. 2010;85(2):114\u20139.","journal-title":"Eur J Haematol"},{"issue":"12","key":"1639_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fern\u00e1ndez de Larrea","year":"2021","unstructured":"Fern\u00e1ndez de Larrea C, Kyle R, Rosi\u00f1ol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):1\u20135.","journal-title":"Blood Cancer J"},{"issue":"27","key":"1639_CR23","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Mor\u00e8 S, Corradini P, et al. High levels of circulating Tumor plasma cells as a key Hallmark of Aggressive Disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(27):3120\u201331.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1639_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood-2023-186411","volume":"142","author":"JJ Garc\u00e9s","year":"2023","unstructured":"Garc\u00e9s JJ, Termini R, Mart\u00edn-S\u00e1nchez E, Lasa M, Perez JJ, Gutierrez NC, et al. Biological and clinical significance of undetectable circulating tumor cells (CTCs) in patients (pts) with multiple myeloma (MM). Blood. 2023;142(Supplement 1):646.","journal-title":"Blood"},{"issue":"10","key":"1639_CR25","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068\u201376.","journal-title":"Blood"},{"issue":"1","key":"1639_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","volume":"132","author":"L Rasche","year":"2018","unstructured":"Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018;132(1):59\u201366.","journal-title":"Blood"},{"issue":"13","key":"1639_CR27","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735.","journal-title":"Blood"},{"issue":"8","key":"1639_CR28","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","volume":"112","author":"B Barlogie","year":"2008","unstructured":"Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112(8):3115.","journal-title":"Blood"},{"issue":"5","key":"1639_CR29","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/cncr.25535","volume":"117","author":"S Waheed","year":"2011","unstructured":"Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, et al. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. Cancer. 2011;117(5):1001\u20139.","journal-title":"Cancer"},{"issue":"10","key":"1639_CR30","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1182\/blood-2002-09-2873","volume":"101","author":"J Shaughnessy","year":"2003","unstructured":"Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood. 2003;101(10):3849\u201356.","journal-title":"Blood"},{"issue":"3","key":"1639_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14740\/jh1007","volume":"11","author":"M Crabtree","year":"2022","unstructured":"Crabtree M, Cai J, Qing X. Conventional karyotyping and fluorescence in situ hybridization for detection of chromosomal abnormalities in multiple myeloma. J Hematol. 2022;11(3):87\u201391.","journal-title":"J Hematol"},{"key":"1639_CR32","doi-asserted-by":"crossref","unstructured":"Cells | Free Full-Text | A Comprehensive Review of the Genomics of Multiple Myeloma. Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics [Internet]. [cited 2024 Aug 9]. Available from: https:\/\/www.mdpi.com\/2073-4409\/10\/8\/1961.","DOI":"10.3390\/cells10081961"},{"issue":"9","key":"1639_CR33","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"},{"issue":"6","key":"1639_CR34","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115(6):762\u201377.","journal-title":"Int J Hematol"},{"key":"1639_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fonc.2020.00189","volume":"10","author":"N Bolli","year":"2020","unstructured":"Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-generation sequencing for clinical management of multiple myeloma: Ready for Prime Time? Front Oncol. 2020;10:189.","journal-title":"Front Oncol"},{"issue":"1","key":"1639_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159\u201370.","journal-title":"Leukemia"},{"issue":"10","key":"1639_CR37","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1158\/1078-0432.CCR-19-1507","volume":"26","author":"EM Boyle","year":"2020","unstructured":"Boyle EM, Ashby C, Tytarenko RG, Deshpande S, Wang H, Wang Y, et al. BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma. Clin Cancer Res. 2020;26(10):2422\u201332.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1639_CR38","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood.2022016212","volume":"141","author":"N Stong","year":"2023","unstructured":"Stong N, Ortiz-Est\u00e9vez M, Towfic F, Samur M, Agarwal A, Corre J, et al. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood. 2023;141(13):1574\u201383.","journal-title":"Blood"},{"issue":"9","key":"1639_CR39","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","volume":"102","author":"S Thanendrarajan","year":"2017","unstructured":"Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102(9):e364\u20137.","journal-title":"Haematologica"},{"issue":"9","key":"1639_CR40","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56(9):1878\u201389.","journal-title":"Nat Genet"},{"issue":"16","key":"1639_CR41","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1182\/blood-2011-03-342089","volume":"118","author":"SK Kumar","year":"2011","unstructured":"Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011;118(16):4359\u201362.","journal-title":"Blood"},{"issue":"4","key":"1639_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12185-011-0948-y","volume":"94","author":"SK Johnson","year":"2011","unstructured":"Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol. 2011;94(4):321\u201333.","journal-title":"Int J Hematol"},{"issue":"6","key":"1639_CR43","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276\u201384.","journal-title":"Blood"},{"issue":"9","key":"1639_CR44","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.clml.2017.06.020","volume":"17","author":"EH van Beers","year":"2017","unstructured":"van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, et al. Prognostic validation of SKY92 and its Combination with ISS in an independent cohort of patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17(9):555\u201362.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"1639_CR45","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406\u201313.","journal-title":"Leukemia"},{"issue":"11","key":"1639_CR46","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/s41375-020-0750-z","volume":"34","author":"V Shah","year":"2020","unstructured":"Shah V, Sherborne AL, Johnson DC, Ellis S, Price A, Chowdhury F, et al. Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia. 2020;34(11):3091\u20136.","journal-title":"Leukemia"},{"issue":"3","key":"1639_CR47","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/jha2.209","volume":"2","author":"N Biran","year":"2021","unstructured":"Biran N, Dhakal B, Lentzsch S, Siegel D, Usmani SZ, Rossi A, et al. Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem. 2021;2(3):375\u201384.","journal-title":"EJHaem"},{"issue":"7","key":"1639_CR48","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1038\/bcj.2016.64","volume":"6","author":"Y Jethava","year":"2016","unstructured":"Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, et al. Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J. 2016;6(7):e453.","journal-title":"Blood Cancer J"},{"issue":"21","key":"1639_CR49","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1182\/blood.V124.21.1199.1199","volume":"124","author":"F van Rhee","year":"2014","unstructured":"van Rhee F, Mitchell A, Heuck C, Grazziutti M, Jethava Y, Khan RZ, et al. Total therapy 4 (TT4) for GEP70-Defined low risk clinical multiple myeloma (CMM): results of patients randomized to a Standard v Light Rrm (S-TT4 v L-TT4). Blood. 2014;124(21):1199.","journal-title":"Blood"},{"issue":"26","key":"1639_CR50","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a Report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1639_CR51","doi-asserted-by":"publisher","unstructured":"Second Revision of the International Staging System (R2-ISS). for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project | Journal of Clinical Oncology [Internet]. [cited 2024 Aug 9]. Available from: https:\/\/doi.org\/10.1200\/JCO.21.02614.","DOI":"10.1200\/JCO.21.02614"},{"issue":"2","key":"1639_CR52","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269\u201377.","journal-title":"Leukemia"},{"key":"1639_CR53","unstructured":"mSMART [Internet]. [cited 2024 Aug 9]. Treatment Guidelines. Available from: https:\/\/www.msmart.org\/mm-treatment-guidelines"},{"issue":"4","key":"1639_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc. 2013;88(4):360\u201376. https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.019.","journal-title":"Mayo Clin Proc"},{"issue":"19","key":"1639_CR55","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.18.00776","volume":"37","author":"A Perrot","year":"2019","unstructured":"Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, et al. Development and validation of a Cytogenetic Prognostic Index Predicting Survival in multiple myeloma. J Clin Oncol. 2019;37(19):1657\u201365.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1639_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587\u201397.","journal-title":"Blood"},{"issue":"1","key":"1639_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00611-x","volume":"12","author":"NH Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):1\u20139.","journal-title":"Blood Cancer J"},{"issue":"4","key":"1639_CR58","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/ajh.27207","volume":"99","author":"X Mao","year":"2024","unstructured":"Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, et al. Development and validation of an individualized and weighted myeloma prognostic score system (MPSS) in patients with newly diagnosed multiple myeloma. Am J Hematol. 2024;99(4):523\u201333.","journal-title":"Am J Hematol"},{"issue":"12","key":"1639_CR59","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","volume":"32","author":"N Bolli","year":"2018","unstructured":"Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32(12):2604\u201316.","journal-title":"Leukemia"},{"issue":"18","key":"1639_CR60","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","volume":"26","author":"M D\u2019Agostino","year":"2020","unstructured":"D\u2019Agostino M, Zaccaria GM, Ziccheddu B, Rustad EH, Genuardi E, Capra A, et al. Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing. Clin Cancer Res. 2020;26(18):4832\u201341.","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"1639_CR61","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood-2022-160130","volume":"140","author":"MF Kaiser","year":"2022","unstructured":"Kaiser MF, Sonneveld P, Cairns D, Raab MS, Larocca A, Brown SR, et al. Co-occurrence of high-risk lesions is a consistent predictor of Ultra-high Risk multiple myeloma in newly diagnosed and Relapsed\/Refractory patients - Meta-analysis of 5,808 trial patients. Blood. 2022;140(Supplement 1):1556\u20138.","journal-title":"Blood"},{"issue":"2","key":"1639_CR62","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/jha2.675","volume":"4","author":"FJ Abu Za\u2019nouneh","year":"2023","unstructured":"Abu Za\u2019nouneh FJ, Ababneh O, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, et al. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023;4(2):454\u20138.","journal-title":"EJHaem"},{"key":"1639_CR63","doi-asserted-by":"publisher","unstructured":"Banerjee R, Cicero KI, Lee SS, Cowan AJ. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling. Front Oncol [Internet]. 2023 Oct 2 [cited 2024 Aug 9];13. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2023.1240966\/full","DOI":"10.3389\/fonc.2023.1240966\/full"},{"issue":"9","key":"1639_CR64","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","volume":"105","author":"J Corre","year":"2020","unstructured":"Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2020;105(9):e480\u20133.","journal-title":"Haematologica"},{"issue":"3","key":"1639_CR65","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.16793","volume":"193","author":"C Bygrave","year":"2021","unstructured":"Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, et al. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol. 2021;193(3):551\u20135.","journal-title":"Br J Haematol"},{"issue":"23","key":"1639_CR66","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988\u201399.","journal-title":"Blood Adv"},{"issue":"10","key":"1639_CR67","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317\u201330.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1639_CR68","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/ajh.27314","volume":"99","author":"BA Costa","year":"2024","unstructured":"Costa BA, Costa TA, Pak K, Patel A, Felix N, Mouhieddine TH, et al. Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: a systematic review and meta-analysis. Am J Hematol. 2024;99(7):1411\u20134.","journal-title":"Am J Hematol"},{"issue":"10","key":"1639_CR69","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.clml.2019.09.004","volume":"19","author":"P Sonneveld","year":"2019","unstructured":"Sonneveld P, Attal M, Perrot A, Hulin C, Caillot D, Facon T, et al. Daratumumab Plus Bortezomib, Thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): Subgroup Analysis of High-risk patients (pts) in CASSIOPEIA. Clin Lymphoma Myeloma Leuk. 2019;19(10):e2\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"1639_CR70","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"8","key":"1639_CR71","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345.","journal-title":"Blood"},{"issue":"1","key":"1639_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01088-6","volume":"14","author":"A Chari","year":"2024","unstructured":"Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024;14(1):1\u201310.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1639_CR73","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(11):e890\u2013901.","journal-title":"Lancet Haematol"},{"issue":"11","key":"1639_CR74","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810\u201321.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"1639_CR75","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, Rosi\u00f1ol L, van der Klift M, Mina R, et al. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023;142(Supplement 1):4.","journal-title":"Blood"},{"issue":"1","key":"1639_CR76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, H\u00e4nel M, Raab MS, Mann C, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2024;42(1):26\u201337.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1639_CR77","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023023597","volume":"143","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien ML, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 2024;143(20):2029\u201336.","journal-title":"Blood"},{"issue":"16suppl","key":"1639_CR78","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2022.40.16_suppl.8002","volume":"40","author":"C Touzeau","year":"2022","unstructured":"Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Caillot D, et al. Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: results of the phase 2 study IFM 2018-04. J Clin Oncol. 2022;40(16suppl):8002\u20138002.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1639_CR79","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","volume":"41","author":"MF Kaiser","year":"2023","unstructured":"Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, et al. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in Ultra-high-risk multiple myeloma. J Clin Oncol. 2023;41(23):3945\u201355.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1639_CR80","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10(10):e825\u201337.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"1639_CR81","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1182\/blood-2022-162339","volume":"140","author":"A Chari","year":"2022","unstructured":"Chari A, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab Plus Lenalidomide, Bortezomib, and dexamethasone (D-RVd) in Transplant-Eligible newly diagnosed multiple myeloma (NDMM) patients (pts): final analysis of Griffin among clinically relevant Subgroups. Blood. 2022;140(Supplement 1):7278\u201381.","journal-title":"Blood"},{"issue":"1","key":"1639_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-024-01030-w","volume":"14","author":"NS Callander","year":"2024","unstructured":"Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, et al. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024;14(1):69.","journal-title":"Blood Cancer J"},{"issue":"Supplement1","key":"1639_CR83","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2019-131887","volume":"134","author":"F van Rhee","year":"2019","unstructured":"van Rhee F, Thanendrarajan S, Schinke CD, Sawyer JR, Rosenthal A, Steward D, et al. EARLY results of TOTAL therapy 7 (TT7): high response rates of NEWLY diagnosed high risk myeloma to Daratumumab. Blood. 2019;134(Supplement1):4569.","journal-title":"Blood"},{"issue":"14","key":"1639_CR84","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and dexamethasone with transplantation for Myeloma. N Engl J Med. 2017;376(14):1311\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"1639_CR85","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and maintenance until Progression in Myeloma. N Engl J Med. 2022;387(2):132\u201347.","journal-title":"N Engl J Med"},{"issue":"6","key":"1639_CR86","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib\u2013melphalan\u2013prednisone, with or without bortezomib\u2013lenalidomide\u2013dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456\u201368.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"1639_CR87","doi-asserted-by":"publisher","first-page":"10144","DOI":"10.1182\/blood-2022-160451","volume":"140","author":"N Callander","year":"2022","unstructured":"Callander N, Silbermann R, Kaufman JL, Godby KN, Laubach JP, Schmidt TM, et al. Analysis of transplant-eligible patients (pts) who received Frontline Daratumumab (DARA)-Based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the Griffin and Master studies. Blood. 2022;140(Supplement 1):10144\u20137.","journal-title":"Blood"},{"issue":"15suppl","key":"1639_CR88","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","volume":"38","author":"P Hari","year":"2020","unstructured":"Hari P, Pasquini MC, Stadtmauer EA, Fraser R, Fei M, Devine SM, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020;38(15suppl):8506\u20138506.","journal-title":"J Clin Oncol"},{"key":"1639_CR89","unstructured":"IMS Events [Internet]. [cited 2025 Jan 4]. Available from: https:\/\/imsannual2024.eventscribe.net\/fsPopup.asp?PresentationID=1496698&returl=YWpheGNhbGxzL3Nlc3Npb25pbmZvLmFzcD9QcmVzZW50YXRpb25JRD0xNDkzODEz&mode=presinfo"},{"key":"1639_CR90","unstructured":"Study Details | MInimal. Residual Disease Adapted Strategy | ClinicalTrials.gov [Internet]. [cited 2024 Aug 11]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04934475"},{"issue":"10","key":"1639_CR91","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","volume":"4","author":"F Gay","year":"2018","unstructured":"Gay F, Jackson G, Rosi\u00f1ol L, Holstein SA, Moreau P, Spada S, et al. Maintenance treatment and survival in patients with myeloma: a systematic review and network Meta-analysis. JAMA Oncol. 2018;4(10):1389\u201397.","journal-title":"JAMA Oncol"},{"issue":"19","key":"1639_CR92","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759\u201369.","journal-title":"N Engl J Med"},{"issue":"19","key":"1639_CR93","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770\u201381.","journal-title":"N Engl J Med"},{"issue":"10","key":"1639_CR94","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895\u2013905.","journal-title":"N Engl J Med"},{"issue":"16","key":"1639_CR95","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617\u201329.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1639_CR96","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10238-024-01445-6","volume":"24","author":"X Gu","year":"2024","unstructured":"Gu X, Tang W, Zhang L, Zheng Y, Pan L, Niu T. Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs. Clin Exp Med. 2024;24(1):179.","journal-title":"Clin Exp Med"},{"issue":"12","key":"1639_CR97","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705\u201320.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1639_CR98","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","volume":"24","author":"D Dytfeld","year":"2023","unstructured":"Dytfeld D, Wr\u00f3bel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(2):139\u201350.","journal-title":"Lancet Oncol"},{"issue":"16suppl","key":"1639_CR99","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1200\/JCO.2023.41.16_suppl.8001","volume":"41","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Joseph NS, Dhodapkar MV, Hofmeister CC, Gupta VA, Andrews JS, et al. Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): a phase 2 study with a safety run-in. J Clin Oncol. 2023;41(16suppl):8001\u20138001.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1639_CR100","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood.2023022080","volume":"143","author":"M D\u2019Agostino","year":"2024","unstructured":"D\u2019Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Mor\u00e8 S, Corradini P, et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood. 2024;143(7):592\u20136.","journal-title":"Blood"},{"issue":"25","key":"1639_CR101","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901\u201312.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1639_CR102","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1182\/bloodadvances.2023011601","volume":"8","author":"S Al Hadidi","year":"2024","unstructured":"Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, et al. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024;8(3):703\u20137.","journal-title":"Blood Adv"},{"issue":"22","key":"1639_CR103","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1639_CR104","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1182\/blood-2018-99-112554","volume":"132","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Sonneveld P, Hungria VTM, Nooka AK, Estell J, Barreto WG, et al. Efficacy and safety of Daratumumab, Bortezomib, and dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse patients: two-year update of Castor. Blood. 2018;132(Supplement 1):3270.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1639_CR105","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1182\/blood-2018-99-112697","volume":"132","author":"N Bahlis","year":"2018","unstructured":"Bahlis N, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, et al. Three-year follow up of the phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (rd) alone in relapsed or refractory multiple myeloma (RRMM). Blood. 2018;132(Supplement 1):1996.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1639_CR106","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1182\/blood-2022-163494","volume":"140","author":"P Moreau","year":"2022","unstructured":"Moreau P, Facon T, Usmani S, Bahlis NJ, Raje N, Plesner T, et al. Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Clinical Assessment of Key subgroups of the phase 3 Maia Study. Blood. 2022;140(Supplement 1):7297\u2013300.","journal-title":"Blood"},{"issue":"Suppl","key":"1639_CR107","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.HS9.0000936164.84357.ed","volume":"7","author":"K Weisel","year":"2023","unstructured":"Weisel K, Kumar S, Moreau P, Bahlis N, Facon T, Plesner T, et al. P09\u2003DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY. HemaSphere. 2023;7(Suppl):14\u20135.","journal-title":"HemaSphere"},{"issue":"11","key":"1639_CR108","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1639_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):1\u201311.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1639_CR110","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","volume":"6","author":"S Giri","year":"2020","unstructured":"Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, et al. Evaluation of Daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and Meta-analysis. JAMA Oncol. 2020;6(11):1759\u201365.","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"1639_CR111","doi-asserted-by":"publisher","first-page":"10157","DOI":"10.1182\/blood-2022-163347","volume":"140","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, San-Miguel J, Cavo M, Blad\u00e9 Creixenti J, Suzuki K, Jakubowiak A, et al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and prednisone (VMP) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Alcyone Study. Blood. 2022;140(Supplement 1):10157\u20139.","journal-title":"Blood"},{"key":"1639_CR112","doi-asserted-by":"crossref","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. 2024.","DOI":"10.1056\/NEJMoa2400712"},{"issue":"1","key":"1639_CR113","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","volume":"8","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021;8(1):e45\u201354.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"1639_CR114","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1182\/blood-2023-179866","volume":"142","author":"MV Mateos","year":"2023","unstructured":"Mateos MV, Paiva B, Cedena Romero MT, Puig N, Sureda Balari AM, Oriol A, et al. GEM2017FIT trial: induction therapy with Bortezomib-Melphalan and Prednisone (VMP) followed by Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus\/Minus Daratumumab (D), 18 cycles, followed by Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years. Blood. 2023;142(Supplement 1):209.","journal-title":"Blood"},{"issue":"1","key":"1639_CR115","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN Guidelines\u00ae insights: multiple myeloma, Version 3.2022. J Natl Compr Cancer Netw JNCCN. 2022;20(1):8\u201319.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"1639_CR116","unstructured":"GSK provides an update on Blenrep (belantamab mafodotin-blmf.) US marketing authorisation | GSK [Internet]. 2022 [cited 2024 Aug 15]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation\/"},{"issue":"10","key":"1639_CR117","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u201312.","journal-title":"Lancet Haematol"},{"issue":"5","key":"1639_CR118","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"1639_CR119","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407.","journal-title":"N Engl J Med"},{"issue":"6","key":"1639_CR120","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"24","key":"1639_CR121","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, Donk NWCJ, van de, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-Cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"11","key":"1639_CR122","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"key":"1639_CR123","unstructured":"Study Details | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus. Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | ClinicalTrials.gov [Internet]. [cited 2024 Aug 15]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06045806"},{"issue":"4","key":"1639_CR124","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1639_CR125","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/blood-2023-180116","volume":"142","author":"P Pham","year":"2023","unstructured":"Pham P, Sudha P, Wang L, Niu W, Morgan C, Ligocki C, et al. Prospective molecular characterization of multiple myeloma patient samples identifies high-risk patients and informs treatment sequences through Resistance mechanisms to immunotherapies. Blood. 2023;142(Supplement 1):4738.","journal-title":"Blood"},{"issue":"5","key":"1639_CR126","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2217\/ijh.14.30","volume":"3","author":"L Agnelli","year":"2014","unstructured":"Agnelli L, Neri A. Next-generation sequencing in multiple myeloma: insights into the Molecular Heterogeneity of the Disease. Int J Hematol Oncol. 2014;3(5):367\u201376.","journal-title":"Int J Hematol Oncol"},{"key":"1639_CR127","unstructured":"Study Details | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd.) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | ClinicalTrials.gov [Internet]. [cited 2024 Aug 11]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04923893"},{"key":"1639_CR128","unstructured":"Study Details |. Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | ClinicalTrials.gov [Internet]. [cited 2024 Aug 11]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05572229"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01639-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T18:35:50Z","timestamp":1743705350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01639-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":128,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01639-5","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"14 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.H reports receiving consulting fees from Jansen, Pfizer and Sanofi. All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}